Multiple Myeloma Side Effects: When Should You Call Your Care Team? | IMS 2026

Multiple Myeloma Side Effects: When Should You Call Your Care Team? | IMS 2026
Second Cancers After Myeloma: Who Faces Higher Risk? | IMS 2026
How Is Myeloma Treatment Changing? Quadruplets, CAR-T, Bispecifics and New Therapies | IMS 2026
Personalized Vaccine for Smoldering Myeloma: Could It Prevent Progression? | IMS 2026
Should You Use the Best Myeloma Treatments Early or Save Them for Relapse?
Talquetamab Taste Changes in Multiple Myeloma: What Helps and What Doesn’t? -TALISMAN Study | #IMS26
Transplant-Ineligible Myeloma: Can Daratumumab + Bortezomib Maintenance Improve Outcomes? | #IMS26
Does Intensive Treatment Affect Quality of Life in High-Risk Myeloma? | RADAR Trial | IMS 2026
Belantamab Mafodotin in Myeloma: Can a Questionnaire Replace Eye Exams? | IMS 2026
What a 3-Month PET-CT Can Predict About CAR-T Outcomes in Multiple Myeloma | IMS 2026
Can Multiple Myeloma Be Cured? MRD Negativity, Stopping Treatment & Confirming Cure | IMS 2026
AL Amyloidosis Bispecific Trial: Who Qualifies, Response , Side Effects & Organ Response | IMS 2026
In Vivo CAR-T for Multiple Myeloma: Could It Improve Access and Skip Chemotherapy? | IMS 2026
Etentamig for Relapsed Multiple Myeloma: New Bispecific Shows Strong Results, Low CRS | IMS 2026
Multiple Myeloma Treatment for Older Adults: Who Should Get Quadruplet Therapy? | IMS 2026
What is Ecotherapy? How Nature Therapy Can Help People With Cancer
